Joshua Patterson
Geen lopende functies
Vermogen: 10 155 $ op 31-03-2024
Profiel
Mr. Joshua F.
Patterson was previously employed as a Chief Compliance Officer & General Counsel by Gamida Cell Ltd., a General Counsel by Akcea Therapeutics, Inc., an Executive Director & Deputy General Counsel by Ionis Pharmaceuticals, Inc., and an In-House Counsel by Amylin Pharmaceuticals, Inc. He received his undergraduate degree from Carthage College and a graduate degree from Syracuse University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
GAMIDA CELL LTD.
0.21% | 15-03-2024 | 282 096 ( 0.21% ) | 10 155 $ | 31-03-2024 |
Eerdere bekende functies van Joshua Patterson
| Bedrijven | Functie | Einde |
|---|---|---|
| GAMIDA CELL LTD. | Compliance Officer | 26-04-2024 |
| IONIS PHARMACEUTICALS, INC. | Director/Board Member | 01-03-2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01-09-2006 |
| AKCEA THERAPEUTICS, INC. | General Counsel | - |
Opleiding van Joshua Patterson
| Carthage College | Undergraduate Degree |
| Syracuse University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
